Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100880 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
A Phase 1 study of Childhood Central Nervous System Germ Cell Tumor and Childhood High-grade Cerebral Astrocytoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT00100880: Completed Phase 1 study of Childhood Central Nervous System Germ Cell Tumor and Childhood High-grade Cerebral Astrocytoma, sponsored by National Cancer Institute (NCI).
NCT00100880 is a Phase 1 study of Childhood Central Nervous System Germ Cell Tumor and Childhood High-grade Cerebral Astrocytoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 45 participants, below the 92-participant average among 3 other Childhood Central Nervous System Germ Cell Tumor trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00100880, a Phase 1 study of Childhood Central Nervous System Germ Cell Tumor and Childhood High-grade Cerebral Astrocytoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with recurrent, progressive, or refractory CNS tumors. Lenalidomide may stop the growth of CNS tumors by blocking blood flow to the tumor. It may also stimulate the immune system in different ways and stop tumor cells from growing.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG lenalidomide
- PROCEDURE diffusion-weighted magnetic resonance imaging
- PROCEDURE perfusion-weighted magnetic resonance imaging
Study Locations (1)
Tennessee
- Pediatric Brain Tumor Consortium - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2004-11 |
| Phase | Phase 1 |
What the finished NCT00100880 record still lists
NCT00100880 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 92-participant average among 3 other Childhood Central Nervous System Germ Cell Tumor trials with a reported enrollment target (51% lower).
The record links to 10 conditions, with Childhood Central Nervous System Germ Cell Tumor appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00100880 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT00100880 about?
NCT00100880 is a clinical study titled "Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors". This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with recurrent, progressive, or refractory CNS tumors. Lenalidomide may stop the growth of CNS tumors by blocking blood flow to the tumor. It may also stimulate the immune system in different way...
What is the current status of trial NCT00100880?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2004-11.
What conditions does trial NCT00100880 study?
This clinical trial studies the following conditions: Childhood Central Nervous System Germ Cell Tumor, Childhood High-grade Cerebral Astrocytoma, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma.
What interventions are being tested in trial NCT00100880?
The interventions under investigation include: laboratory biomarker analysis (OTHER), lenalidomide (DRUG), diffusion-weighted magnetic resonance imaging (PROCEDURE), perfusion-weighted magnetic resonance imaging (PROCEDURE).
Who is sponsoring clinical trial NCT00100880?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00100880 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Childhood Central Nervous System Germ Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
COMPLETED · Phase 1
-
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
COMPLETED · Phase 1
-
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia